Jazz Pharmaceuticals PLC (JAZZ) - What Are Analysts Thinking About This Stock?

Key Points

• Analysts remain bullish: Twenty analysts give Jazz Pharmaceuticals a consensus “Buy” rating, with 18 buys, one hold and one strong buy. The average 12-month price target is $291.25, with recent targets ranging from $271 to $337.
• Quarterly results were mixed: Jazz reported $5.71 in adjusted EPS, below the $6.18 consensus estimate, but revenue of $1.21 billion exceeded expectations and rose 15.5% year over year.
• Ownership activity was notable: Insiders sold roughly 100,121 shares worth $24.9 million over the past 90 days, while institutional investors still own a substantial 89.14% of the company.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) have received a consensus rating of "Buy" from the twenty analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $291.25.

Several research firms have recently commented on JAZZ. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the company an "overweight" rating in a research report on Tuesday, August 4th. Stifel Nicolaus set a $275.00 price objective on Jazz Pharmaceuticals in a report on Tuesday, August 4th. Canaccord Genuity Group set a $300.00 price objective on Jazz Pharmaceuticals in a research report on Wednesday, August 26th. The Goldman Sachs Group started coverage on Jazz Pharmaceuticals in a research report on Thursday, September 24th. They issued a "buy" rating and a $337.00 price objective for the company. Finally, Barclays raised their target price on Jazz Pharmaceuticals from $270.00 to $271.00 and gave the stock an "overweight" rating in a research note on Thursday, September 10th.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $209.65 on Thursday. Jazz Pharmaceuticals has a 12-month low of $128.80 and a 12-month high of $266.38. The stock has a market cap of $13.61 billion, a P/E ratio of 14.46, a PEG ratio of 0.21 and a beta of 0.37. The company has a 50-day moving average price of $241.51 and a 200 day moving average price of $231.86. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts' consensus estimates of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to analysts' expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. Jazz Pharmaceuticals's revenue for the quarter was up 15.5% on a year-over-year basis. During the same period last year, the firm earned ($8.25) earnings per share. Sell-side analysts anticipate that Jazz Pharmaceuticals will post 21.59 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the completion of the transaction, the director directly owned 345,875 shares in the company, valued at approximately $79,665,388.75. This represents a 1.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 2,000 shares of the firm's stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $236.40, for a total value of $472,800.00. Following the sale, the chief executive officer directly owned 141,394 shares of the company's stock, valued at $33,425,541.60. The trade was a 1.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 100,121 shares of company stock worth $24,855,802 over the last ninety days. Company insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Triumph Capital Management lifted its stake in Jazz Pharmaceuticals by 2.0% during the 2nd quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company's stock worth $626,000 after acquiring an additional 52 shares in the last quarter. Bessemer Group Inc. grew its position in Jazz Pharmaceuticals by 0.3% in the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company's stock valued at $4,228,000 after acquiring an additional 73 shares in the last quarter. Fifth Third Wealth Advisors LLC grew its position in Jazz Pharmaceuticals by 4.4% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company's stock valued at $377,000 after acquiring an additional 85 shares in the last quarter. Root Financial Partners LLC grew its position in Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company's stock valued at $56,000 after acquiring an additional 89 shares in the last quarter. Finally, Syon Capital LLC grew its position in Jazz Pharmaceuticals by 7.4% in the 2nd quarter. Syon Capital LLC now owns 1,507 shares of the specialty pharmaceutical company's stock valued at $363,000 after acquiring an additional 104 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz's neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.